Total Payments
$53,819
2024 Payments
$6,119
Companies
14
Transactions
57
Medicare Patients
990
Medicare Billing
$117,072
Payment Breakdown by Category
Consulting$42,997 (79.9%)
Travel$4,718 (8.8%)
Other$3,243 (6.0%)
Research$1,813 (3.4%)
Food & Beverage$1,047 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $42,997 | 13 | 79.9% |
| Travel and Lodging | $4,718 | 18 | 8.8% |
| Honoraria | $3,200 | 1 | 5.9% |
| Unspecified | $1,813 | 3 | 3.4% |
| Food and Beverage | $1,047 | 21 | 1.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $43.36 | 1 | 0.1% |
Payments by Type
General
$52,006
54 transactions
Research
$1,813
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $10,028 | 2 | $0 (2021) |
| ABBVIE INC. | $8,586 | 14 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,911 | 4 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $7,371 | 3 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,995 | 2 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $3,934 | 9 | $0 (2018) |
| Alexion Pharmaceuticals, Inc. | $3,609 | 2 | $0 (2017) |
| Janssen Global Services, LLC | $2,740 | 1 | $0 (2022) |
| Kite Pharma, Inc. | $2,186 | 5 | $0 (2018) |
| Verastem, Inc. | $884.06 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,119 | 3 | ABBVIE INC. ($6,119) |
| 2023 | $2,467 | 11 | AbbVie Inc. ($2,467) |
| 2022 | $3,560 | 3 | Janssen Global Services, LLC ($2,740) |
| 2021 | $3,426 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($2,355) |
| 2020 | $10,011 | 4 | Novartis Pharmaceuticals Corporation ($7,371) |
| 2019 | $8,038 | 7 | AstraZeneca Pharmaceuticals LP ($7,091) |
| 2018 | $15,707 | 18 | AstraZeneca UK Limited ($9,000) |
| 2017 | $4,492 | 8 | Alexion Pharmaceuticals, Inc. ($3,609) |
All Payment Transactions
57 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $55.71 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $6,050.00 | General |
| 11/05/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $822.20 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $226.78 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $159.32 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $369.55 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $369.55 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $244.00 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $152.32 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $134.98 | General |
| Category: Oncology | ||||||
| 09/13/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 01/14/2022 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 07/21/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| 06/21/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $43.36 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2020 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| 12/07/2020 | Novartis Pharmaceuticals Corporation | VAY736 (Drug) | — | In-kind items and services | $964.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 10/22/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| 08/07/2020 | Novartis Pharmaceuticals Corporation | VAY736 (Drug) | — | In-kind items and services | $407.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 12/10/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $5,480.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,371 | 2 |
| CC-122-CLL-001 - Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations CC-122 AND Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocyti | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 251 | 424 | $134,818 | $32,937 |
| 2022 | 3 | 189 | 329 | $83,788 | $26,393 |
| 2021 | 3 | 247 | 376 | $73,641 | $25,743 |
| 2020 | 4 | 303 | 550 | $107,175 | $31,999 |
Total Patients
990
Total Services
1,679
Medicare Billing
$117,072
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 179 | 334 | $101,202 | $22,765 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 67 | $23,450 | $7,191 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $10,166 | $2,981 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 144 | 278 | $65,804 | $20,426 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 32 | 38 | $12,388 | $4,107 | 33.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $5,596 | $1,860 | 33.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 224 | 320 | $62,424 | $22,159 | 35.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 44 | $7,920 | $2,484 | 31.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 12 | $3,297 | $1,101 | 33.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 258 | 450 | $87,750 | $25,421 | 29.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 62 | $10,850 | $3,562 | 32.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 20 | 23 | $6,325 | $2,074 | 32.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 14 | 15 | $2,250 | $943.28 | 41.9% |
About Dr. John Byrd, M.D
Dr. John Byrd, M.D is a Hematology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770599664.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Byrd, M.D has received a total of $53,819 in payments from pharmaceutical and medical device companies, with $6,119 received in 2024. These payments were reported across 57 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($42,997).
As a Medicare-enrolled provider, Byrd has provided services to 990 Medicare beneficiaries, totaling 1,679 services with total Medicare billing of $117,072. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology
- Location Pittsburgh, PA
- Active Since 07/31/2006
- Last Updated 02/03/2026
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1770599664
Products in Payments
- CALQUENCE (Drug) $7,911
- Imbruvica (Drug) $3,934
- Strensiq (Drug) $3,609
- VENCLEXTA (Drug) $2,536
- VAY736 (Drug) $1,371
- Copiktra (Drug) $884.06
- CC-122 (Drug) $442.00
- TIBSOVO (Drug) $43.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Pittsburgh
Robert Kaplan, Md, MD
Hematology — Payments: $105,841
Hematology $105,841
Craig Seaman, M.d, M.D
Hematology — Payments: $83,730
Hematology $83,730
Dr. Laura Decastro, M.d, M.D
Hematology — Payments: $23,132
Hematology $23,132
Santhosh Sadashiv, Md, MD
Hematology — Payments: $21,349
Hematology $21,349
Ranjita Pallavi, M.d, M.D
Hematology — Payments: $4,797
Hematology $4,797
Dr. Olukemi Esan, M.b.,B.s, M.B.,B.S
Hematology — Payments: $102.84
Hematology $102.84